Activation Of Protective Innate-adaptive Immunity Duo For Conferring Rapid-sustained-broad Protection Of Vaccines Against Infectious Agents | 36065
Journal of Clinical & Cellular Immunology
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
We report that intranasal administration of an E1/E3-defective (ΔE1E3) adenovirus serotype 5 (Ad5)-vectored influenza
vaccine could induce seroconversion in human volunteers without appreciable adverse effects, even in subjects with
pre-existing Ad5 immunity. Mice and ferrets were well protected against challenge by a lethal dose of an H5N1 avian influenza
virus following intranasal instillation of an Ad5 vector encoding hemagglutinin (HA) in a single-dose regimen. Moreover, the
ΔE1E3 Ad5 particle itself without transgene could confer rapid-sustained-broad protection against influenza by inducing an
anti-influenza state in a drug-like manner, conceivably by activating a specific arm of innate immunity. An Ad5 vector encoding
HA thus consolidates drug and vaccine into a single package, which allows the Ad5 backbone to induce protective innate
immunity capable of conferring nearly-immediate and prolonged (e.g., 1-47 days) protection as the first wave against influenza;
followed by HA-mediated adaptive immunity as the second wave before the innate immunity-associated anti-influenza state
declines away. Overall, the work conceivably would foster the development of a novel noninvasive drug-vaccine duo platform
technology capable of conferring rapid-sustained-broad protection against pathogens with neither the potential to induce drug
resistance nor that to trigger harmful systemic inflammation.
De-chu Christopher Tang founded VaxDome LLC in 2014 and Vaxin Inc. in 1997 in Birmingham, Alabama. He was an Assistant/Associate Professor at University of Alabama at Birmingham (1994-2004). He was one of the pioneers during the development of DNA vaccines, noninvasive skin-patch vaccines, adenovirusvectored nasal vaccines, adenovirus-vectored poultry vaccines, as well as the protective innate-adaptive immunity duo platform technology. He was selected as a Distinguished Overseas Scientist by the South Korea KOFST Brain Pool Program in 2012; and was appointed as a Scientist at International Vaccine Institute in 2013.